MedDataX Logo

MRI in Staging Ovarian Cancer Using MRI Contrast Agent

NCT ID: NCT00463996

Last Updated: 2007-04-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-04-30

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Can MRI be used to stage ovarian cancer?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Staging of ovarian cancer can best be performed with CT or MRI compared to ultrasound. Studies have shown an increase in pos. predictive value by adding contrast i.v. to the MR-examination protocol. We compare staging of ovarian cancer by 1.MRI without contrast (standard method) to 2.MRI with contrast agent i.v. (new method)in the same patient. Golden standard are findings at operation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* suspicion of ovarian cancer

Exclusion Criteria

* recurrence of disease
* contraindication to MRI, contrast agent
* inoperable patients for other reasons
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Aarhus

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Liselotte Ibsen, doc

Role: PRINCIPAL_INVESTIGATOR

Aarhus University Hospital, BDA, Skejby

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Liselotte Ibsen, doc

Role: CONTACT

+4589495201

Erik Lundorf, consultant

Role: CONTACT

[email protected]
+4589495251

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MR-Center-001

Identifier Type: -

Identifier Source: org_study_id